ICON Public Limited Company (NASDAQ:ICLR) Q1 2024 Earnings Call Transcript

Steve Cutler: Yeah. Jailendra, I won’t profess to be an expert in the implications of the BIOSECURE Act, but there are potential issues. I think, it’s probably more for our pharma — it’s more a question for our pharma customers in terms of their access to CDMOs and those sorts of organizations. And the potential, particularly, I think in China, for some challenges in terms of supply. And, I guess, if it’s supply of their drug product, there may potentially be some implications for supply of clinical trial supplies. But, really, our pharma brethren are pretty smart people and they plan very well for these sorts of things. So, I’d be very surprised if we saw any really material impact. I know, there are some concerns about it, they’ve expressed those to the government.

But I think the supply chain challenge, I think, has been ongoing now for several years. And I think they’re thinking, and I think they’ve already thought very hard about where they get, particularly the manufacturing of their drug and their APIs done. And so I don’t see much implication for us, certainly in the short term.

Jailendra Singh: Thank you.

Steve Cutler: Okay. So, I think we’re at the end of the question. So, thank you, operator. We will — I want to thank you all for joining our call today and for your continued interest in ICON. We look forward to seeing many of you at our upcoming Investor Day in New York City, and providing you with an opportunity to spotlight the important work we do here at ICON. Thank you, all, and have a good day.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect. Speakers, please stand by.